Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05399368 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
A Phase 2 study, sponsored by RAPT Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
NCT05399368: Clinical Trial Phase 2 study, sponsored by RAPT Therapeutics.
NCT05399368 is a Phase 2 study that was terminated before completion, run by RAPT Therapeutics. The registered enrollment target is 229 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05399368, a Phase 2 study, was terminated before completion, sponsored by RAPT Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
Study Summary
Phase 2 study of RPT193 in adults with atopic dermatitis
Primary Outcome
% change in Eczema Area Severity Index (EASI) from baseline at Week 16
Interventions
- OTHER Placebo
- DRUG RPT193
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2024-05-24 |
| Phase | Phase 2 |
Why NCT05399368 stopped before completion
NCT05399368 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05399368 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05399368 about?
NCT05399368 is a clinical study titled "An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis". Phase 2 study of RPT193 in adults with atopic dermatitis
What is the current status of trial NCT05399368?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2022-06-07. Estimated completion is 2024-05-24.
What interventions are being tested in trial NCT05399368?
The interventions under investigation include: Placebo (OTHER), RPT193 (DRUG).
Who is sponsoring clinical trial NCT05399368?
This trial is sponsored by RAPT Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05399368's enrollment target sits among peer trials
229 264th of 2000 higher than 1,737 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI